Comparative Bioavailability of Tizanidine in Three Dosage Forms (6-MG Delayed-Release Tablets, Sirdalud Preparation, and 2-MG Tablets)
- Autores: Kukes V.1, Reikhart D.2, Artnautov V.1, Torshina E.1, Kapashin A.1, Belostotskii A.2
-
Afiliações:
- Valenta Pharm Joint-Stock Company
- I. M. Sechenov First Moscow State Medical University
- Edição: Volume 50, Nº 6 (2016)
- Páginas: 394-403
- Seção: Article
- URL: https://journals.rcsi.science/0091-150X/article/view/244403
- DOI: https://doi.org/10.1007/s11094-016-1458-2
- ID: 244403
Citar
Resumo
Valenta Pharm Co. compared the pharmacokinetic parameters in healthy volunteers of three prototype tizanidine dosage forms (delayed-release 6-mg tablets) and the reference drug sirdalud (2-mg tablets for a total dose of 6 mg, three tablets). This allowed the relative bioavailability of the three prototype tizanidine forms relative to sirdalud to be assessed. All three prototypes showed signs of delay based on MRT parameters of (2.217 ± 0.441) h for the sirdalud instant-release form and (6.529 ± 1.990), (5.951 ± 1.295), and (6.384 ± 2.339) h for prototypes T1, T2, and T3, respectively. High relative exposure levels of prototypes T1, T2, and T3 [AUC 103.80% (73.69 – 146.20), 124.14% (88.14 – 174.86), and 131.93% (93.66 – 185.82), respectively] with a significant decrease of Cmax (to 35.83, 38.78, and 40.79%, respectively) were demonstrated by analyzing the comparative bioavailability. A model pharmacokinetic study of the forms produced secondary modeling parameters that were similar to those obtained by an off-model method (89.19 – 122.71%). This confirmed that the developed model was acceptable for planning future clinical tests of these drugs.
Palavras-chave
Sobre autores
V. Kukes
Valenta Pharm Joint-Stock Company
Email: chem@folium.ru
Rússia, 18/2 Ochakovskoe Shosse, Moscow, 119530
D. Reikhart
I. M. Sechenov First Moscow State Medical University
Email: chem@folium.ru
Rússia, Moscow, 2/4 B. Pirogovskaya St., 119991
V. Artnautov
Valenta Pharm Joint-Stock Company
Email: chem@folium.ru
Rússia, 18/2 Ochakovskoe Shosse, Moscow, 119530
E. Torshina
Valenta Pharm Joint-Stock Company
Email: chem@folium.ru
Rússia, 18/2 Ochakovskoe Shosse, Moscow, 119530
A. Kapashin
Valenta Pharm Joint-Stock Company
Email: chem@folium.ru
Rússia, 18/2 Ochakovskoe Shosse, Moscow, 119530
A. Belostotskii
I. M. Sechenov First Moscow State Medical University
Email: chem@folium.ru
Rússia, Moscow, 2/4 B. Pirogovskaya St., 119991